Dyne Therapeutics
Highly Engaged Employees
Highly Engaged EmployeesManufacturing · Massachusetts, United States · 201-500 Employees
View Company Info for Free
Overview
Headquarters
1560 Trapelo Rd, Waltham, Massachusetts,...Phone Number
(781) 786-8230Website
www.dyne-tx.comRevenue
-Stock Symbol
DYNIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
7
1
1
2
1
1
About Dyne Therapeutics
Founded in 2018, Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to muscle tissue seen with other approachesExplore more
Dyne Therapeutics Org Chart
RB
Chief Scientific Officer
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Dyne Therapeutics your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Dyne Therapeutics is spiking on competitors!
Check if Dyne Therapeutics has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Click to see if Dyne Therapeutics had a recent Job posting/layoffs
Product Launch: Get notified when Dyne Therapeutics launches new products
Congratulate Masked Content for being promoted to Masked Content at Dyne Therapeutics
Dyne Therapeutics, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on Dyne Therapeutics recently announced quarterly report
Funding: Get notified immidiatlly once Dyne Therapeutics has new funding data
Recommended Actions
Find VP level buyers at Dyne Therapeutics
Find 2 more new buyers
Compare Similar Companies to Dyne Therapeutics
Compare insights from companies similar to Dyne Therapeutics, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Dyne Therapeutics is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Dyne Therapeutics is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Dyne Therapeutics.
Dyne Therapeutics financials insights
Gather financial insights about Dyne Therapeutics, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2019
Series A
$50M
2020
Other Financing Round
$115M
Stock Offering
$233M
2025
Stock/Share Issuance
$505M
2026
Debt
$50M
Dyne Therapeutics Tech Stack
A closer look at the technologies used by Dyne Therapeutics
Most Recent Scoops
Open Position
Funding
Funding
Open Position
Open Position
Open Position
Dyne Therapeutics News & Media
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares
WALTHAM, Mass., July 23, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the closing of its previously announced upsized underwritten public offering of 21,045,000 shares of its common stock at a public offering price of $20.50 per share, which includes 2,745,000 shares issued upon the exercise in full by the underwriters of theirDyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the pricing of an upsized underwritten public offering of 18,300,000 shares of its common stock at a public offering price of $20.50 per share. The gross proceeds to Dyne from the offering, before deducting underwriting discounts and commissions and offeringDyne Therapeutics Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., July 21, 2026 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced that it has commenced an underwritten public offering of $300,000,000 of shares of its common stock. Dyne also intends to grant the underwriters a 30-day option to purchase up to an additional $45,000,000 of shares of its common stock. All of the shares inDyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)
- Priority Review granted; PDUFA target action date set for January 21, 2027 -
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Dyne Therapeutics
Sign Up For FreeTo access detailed company insights
Founded in 2018, Dyne Therapeutics is building a leading muscle disease company dedicated to advancing innovative life-transforming therapeutics for people living with genetically driven diseases. With its proprietary FORCE platform, Dyne is developing modern oligonucleotide therapeutics that are designed to overcome limitations in delivery to musc... Read More
